Stem cell therapy for novel coronavirus pneumonia has shown significant results.

Recently, a study by Wang Fusheng, academician of the Chinese Academy of Sciences, director of the diagnosis, treatment and Research Center for infectious diseases of the fifth medical center of the PLA General Hospital, and director of the National Clinical Research Center for infectious diseases, was published in Springer nature’s signal transduction and targeted therapy

.

Novel coronavirus pneumonia (UC-MSC) is a new II phase in the treatment of severe novel coronavirus pneumonia

.

The results showed that novel coronavirus pneumonia could significantly improve lung injury in patients with severe novel coronavirus pneumonia

.

The study suggests that novel coronavirus pneumonia has accelerated the regression of pulmonary solid lesions in UC-MSC patients, improved the comprehensive reserve capacity of lung, and confirmed the good tolerance and safety

.

Stem cell therapy can provide a safe and potentially effective treatment option for patients with COVID-19 lung injury

.

This article is entitled novel coronavirus pneumonia in patients with severe acute lung injury in COVID-19: a randomized, double-blind, placebo-controlled phase II trial, which is the first double-blind, randomized controlled phase II trial for patients with newly diagnosed pneumonia associated with lung injury

.

Novel coronavirus pneumonia stem cell therapy clinical trials with the largest sample size were reported in the clinical trial

.

The final sample size was 100

.

Regarding UC-MSC’s novel coronavirus pneumonia in the treatment group, the author said in his paper: “data have found that UC-MSC is safe and well tolerated and shows an improved trend in all lung injury patients with novel coronavirus pneumonia

.

Compared with placebo, uc-msc significantly improved the regression of pulmonary solid component lesions It is understood that the phase II clinical trial is based on the results of a parallel controlled, non randomized, phase I clinical study published by Wang Fusheng’s team in the same journal in August 2020

.

Novel coronavirus pneumonia is a safe and tolerable drug for patients with moderate and severe novel coronavirus pneumonia, preliminary studies confirm

.

UC-MSC In addition, novel coronavirus pneumonia patients with UC-MSC treated with I have shown some potential benefits of some clinical indicators

.

Therefore, novel coronavirus pneumonia is a new method for the treatment of severe acute respiratory syndrome

.

The novel coronavirus pneumonia patients in the II phase of clinical trials were included in the March 5, 2020 phase to March 28, 2020

.

The most severe hospitalized patients in Wuhan were in recovery stage, and some of them were in progress

.

Compared with the phase I study, the patients recruited in this study were all severe patients with longer duration and older age

.

In particular, all patients have severe lung injury and need oxygen support during the course of the disease

.

Novel coronavirus pneumonia has been approved by the US FDA for the extended use of sympathies in patients with novel coronavirus pneumonia

.

The authors also believe novel coronavirus pneumonia is needed for phase III clinical trials to further assess the impact of mortality and long-term lung injury prevention, and explore the potential mechanism of umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia

.

The study was approved by the clinical trial ethics committee of the fifth medical center of the General Hospital of the Chinese people’s Liberation Army, the medical ethics committee of Wuhan huoshenshan hospital, and the medical ethics committee of Hubei maternal and child health care hospital

.

Umbilical cord mesenchymal stem cells used in this experiment were all provided by Zhongyuan Xiehe cell genetic engineering Co., Ltd

.

Wang Fusheng, Xie Weifen, Professor of Changzheng Hospital of Naval Medical University, and Yao Chen, Professor of Clinical Research Institute of Peking University are the co corresponding authors

.

Shi Lei, associate professor of the fifth medical center of PLA General Hospital, Huang Hai, associate professor of Changzheng Hospital of Naval Medical University, Lu Xuechun, Professor of the second medical center of PLA General Hospital, and Yan Xiaoyan, Senior Statistician of Peking University Clinical Research Institute are the co first authors of this paper

.

Related papers information: https://doi.org/10.1038/s41392-021-00488-5 Recommended attention: 2021 iebmbt and Biotechnology Exhibition: introduction to the exhibition of biological materials of 2021 iebmbt

.

Please scan the middle QR code for the audience to attend the exhibition

.

< br > exhibition consultation: 13917763626 Mr

.

Jiang 13472720506 Mr

.

Jing 15900766480 Mr

.

Ye consultation on meeting affairs and study classes: 18928523 Mr

.

He 15821275113 Mr

.

Shen media or other cooperation: 13482154098 D ory@aitectt.com Join the community: scan QR code, add and edit wechat.

.